Sosina Makonnen

Medicine · Health Sciences

14h-index1.1kcitations42works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(11), Monoclonal and Polyclonal Antibodies Research(10), Liver physiology and pathology(9), Cancer Research and Treatments(9), CAR-T cell therapy research(8)

Publications42 total

Table S2 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Table S1 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Supplementary Data from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Figure S3 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Table S4 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Figure S2 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Data from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Table S3 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Figure S1 from A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
2025Open Access
Data from Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054
2023Open Access
Data from Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054
2023Open Access
Supplementary Data from Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054
2023Open Access
Supplementary Data from Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054
2023Open Access
Supplementary Figure S1 - S8 from Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers
2023Open Access
Data from Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers
2023Open Access
Data from Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers
2023Open Access
Supplementary Figure S1 - S8 from Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers
2023Open Access
Supplementary Methods from Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers
2023Open Access
Supplementary Methods from Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers
2023Open Access
Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054
Cancer Immunology Research·2022· 22 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Marcus P. Kelly(33), Carlos Hickey(33), Gavin Thurston(33), Jason T. Giurleo(30), William C. Olson(24), Frank J. Delfino(23), Jessica R. Kirshner(23), Thomas Nittoli(21), Arthur Kunz(21), Marc W. Retter(14), Terra Potocky(13), Shu Mao(13), Feng Zhao(13), Zhaoyuan Chen(12), Pamela Krueger(11), Richard Tavaré(11), Dangshe Ma(10), John O. DaSilva(10), Katie Yang(10), Oliver Surriga(10)